Cortechs.ai | Cortechs.ai announces Health Canada/Santé Canada license for NeuroQuant<sup>®</sup>

Cortechs.ai announces Health Canada/Santé Canada license for NeuroQuant®

Cortechs.ai expands market reach into Canada for NeuroQuant, the leading volumetric brain imaging solution for MRIs.

(SAN DIEGO) Feb. 2, 2016 – Cortechs.ai, the leading medical software innovator providing solutions for quantitative brain volume analysis, is pleased to announce that it has received Health Canada/Santé Canada Medical Device License for marketing and distribution of NeuroQuant® in Canada. Already FDA cleared and CE marked, NeuroQuant is used throughout the world by physicians in hundreds of reputable clinics and hospitals to help in their assessment of neurodegeneration.

Fully automated, NeuroQuant provides neurologists, radiologists, and clinical researchers with an accurate and convenient tool to quantify the volumes of specific brain structures in order to better assess neurological conditions such as Alzheimer’s disease, brain trauma, multiple sclerosis, epilepsy and brain development.

“The Heath Canada/Santé Canada Medical Device License is a testament to our commitment to quality, safety and performance and now allows customers in Canada to start using NeuroQuant in their clinical practice,” commented Guri Stark, CEO of Cortechs.ai. “We are excited to introduce our innovative brain imaging solution to Canadian hospitals, clinics and universities and expand access to proven and reliable quantitative volumetric analysis of neurological conditions via MR imaging.”

About Cortechs.ai

Cortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of MRI images of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis provides neurologists, radiologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma and brain development. Please visit cortechs.ai for further information.

###

Contact: Travis Foegler
Phone: +1 (619) 450-9094
Email: [email protected]

More Resources

08/18/2025

Why Bigger Normative Databases Mean Better Brain Imaging

NeuroQuant® 5.2 compares patient brain MRI volumes to over 7,000 healthy scans, giving clinicians clear, percentile-based context for better assessments.

08/07/2025

Navigating Reimbursement for NeuroQuant: Understanding CPT Codes 0865T & 0866T 

Let’s break down the latest category III CPT codes and example clinical use cases that illustrate their value.

07/31/2025

Precision Without the Pressure: Smarter Brain Tumor Monitoring

Learn about NeuroQuant Brain Tumor 2.0 and how it assists clinicians by providing objective quantification and analysis of tumor changes over time.

07/30/2025

Cortechs.ai Announce Next-Gen NeuroQuant Brain Tumor: AI-Driven Metastasis & Meningioma Segmentation 

NeuroQuant Brain Tumor is the first FDA-cleared, cloud-native tool to offer automated volumetric segmentation for brain metastases, meningiomas, and gliomas.

07/28/2025

Longitudinal Assessment of Traumatic Brain Injury Using NeuroQuant®

A case study with Dr. Suzie Bash on NeuroQuant as a reliable, reimbursable, and efficient tool in the evaluation and follow-up of TBI.

07/24/2025

Understanding the Hippocampal Occupancy Score

One of the most frequently asked questions among customers is, “What does the Hippocampal Occupancy Score (HOC) represent within the Dementia Report?”
Scroll to Top